Forearm reactive hyperemia and mortality in end-stage renal disease

被引:114
|
作者
London, GM
Pannier, B
Agharazii, M
Guerin, AP
Verbeke, FHM
Marchais, SJ
机构
[1] Hop Manhes, Serv Nephrol Hemodialyse, F-91700 Fleury Merogis, France
[2] CHUQ Hotel Dieu Quebec, Quebec City, PQ, Canada
[3] State Univ Ghent Hosp, B-9000 Ghent, Belgium
关键词
vasodilation; endothelium; kidney; mortality;
D O I
10.1111/j.1523-1755.2004.00434.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Reports on the general population indicated that decreased endothelial-mediated vasodilation has a prognostic impact on cardiovascular (CV) morbidity and mortality. Flow-dependent vasodilation of conduit arteries and ischemia-induced forearm reactive hyperemia are impaired in end-stage renal disease (ESRD). Whether deterioration of vasodilator function in ESRD patients has a prognostic impact has not been documented. The aim of this study was to determine whether the impaired forearm postischemic vasodilation is an independent predictor of mortality in ESRD patients, independently from CV end-organ damages, which are usually associated with decreased vasodilatory response. Methods. Common carotid artery intima-media thickness (CCA-IMT), aortic stiffness (pulse wave velocity - PWV), and LV mass (LVM) were determined for 78 stable ESRD patients on hemodialysis. Forearm postischemic vasodilation [flow debt repayment (FDR)] was measured by venous plethysmography. All-cause mortality served as the outcome variable over a median follow-up of 60 +/- 27 months. Results. Twenty-four deaths occured (16 of CV origin). According to Cox regression adjusted for age, CCA-IMT, LVM, and PWV, all-cause mortality was independently associated with decreased FDR (RR 0.69 for every 10% increase; 95% CI 0.56- 0.85; P = 0.0006) and increased aortic PWV (RR 1.16 for 1 m/s increase; 95% CI 1.04-1.29; P = 0.0091). Conclusion. Our data indicate that lower postischemic forearm reactive hyperemia is associated with all-cause mortality of ESRD patients, independently of the presence of end-organ damage such as LVH or arteriosclerosis.
引用
收藏
页码:700 / 704
页数:5
相关论文
共 50 条
  • [1] Reactive hyperemia and mortality in end-stage renal disease (ESRD) patients
    Guerin, AP
    Pannier, BM
    London, GM
    Marchais, SJ
    Adda, H
    Metivier, F
    JOURNAL OF HYPERTENSION, 2003, 21 : S215 - S215
  • [2] Cardiovascular mortality in end-stage renal disease
    Collins, AJ
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2003, 325 (04): : 163 - 167
  • [3] Depression and Mortality in End-Stage Renal Disease
    Halen, Nisha Ver
    Cukor, Daniel
    Constantiner, Melissa
    Kimmel, Paul L.
    CURRENT PSYCHIATRY REPORTS, 2012, 14 (01) : 36 - 44
  • [4] Depression and Mortality in End-Stage Renal Disease
    Nisha Ver Halen
    Daniel Cukor
    Melissa Constantiner
    Paul L. Kimmel
    Current Psychiatry Reports, 2012, 14 : 36 - 44
  • [5] Hemoglobin variability and mortality in end-stage renal disease
    不详
    Nature Clinical Practice Nephrology, 2008, 4 (3): : 122 - 123
  • [6] Mortality and treatment modality of end-stage renal disease
    Schulman, G
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (03) : 229 - 231
  • [7] Is ghrelin a biomarker for mortality in end-stage renal disease?
    Mak, Robert H.
    Cheung, Wai W.
    KIDNEY INTERNATIONAL, 2011, 79 (07) : 697 - 699
  • [8] Hypocalcemia, morbidity, and mortality in end-stage renal disease
    Foley, RN
    Parfrey, PS
    Harnett, JD
    Kent, GM
    Hu, LQ
    ODea, R
    Murray, DC
    Barre, PE
    AMERICAN JOURNAL OF NEPHROLOGY, 1996, 16 (05) : 386 - 393
  • [9] C-reactive protein and end-stage renal disease
    Lacson, E
    Levin, NW
    SEMINARS IN DIALYSIS, 2004, 17 (06) : 438 - 448
  • [10] Trends in end-stage renal disease - Epidemiology, morbidity, and mortality
    Reikes, ST
    POSTGRADUATE MEDICINE, 2000, 108 (01) : 124 - +